~~<i id='10BC87C76C'><strike id='10BC87C76C'><tt id='10BC87C76C'><pre id='10BC87C76C'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：explore 2025-10-01 13:18:00 Page View：88657

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The mammogram wars are not over
Next article： Anesthesiologist group: stop taking Ozempic before surgery

focus

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Timeline: Special counsel's probe into Trump's handling of classified documents

1:00InthisJune9,2023,filephoto,specialcounselJackSmithspeakstoreportersinWashington,D.C.JoseLuisMaga

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

Israel demolishes home of alleged Palestinian attacker, fueling West Bank tensions

RAMALLAH,WestBank--IsraelisecurityforcesonTuesdaydemolishedtheWestBankhomeofaPalestinianmanaccusedof